NASDAQ:SUPN

Supernus Pharmaceuticals News Headlines

$31.74
-0.23 (-0.72 %)
(As of 06/15/2021 03:20 PM ET)
Add
Compare
Today's Range
$31.38
$31.93
50-Day Range
$27.97
$32.26
52-Week Range
$17.20
$32.31
Volume11,097 shs
Average Volume539,990 shs
Market Capitalization$1.68 billion
P/E Ratio15.33
Dividend YieldN/A
Beta1.25

Supernus Pharmaceuticals (NASDAQ SUPN) News Headlines Today

SourceHeadline
Supernus Pharmaceuticals Stock Getting Closer To Key Technical MeasureSupernus Pharmaceuticals Stock Getting Closer To Key Technical Measure
finance.yahoo.com - June 10 at 1:57 PM
 Analysts Expect Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Will Post Quarterly Sales of $134.83 Million Analysts Expect Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Will Post Quarterly Sales of $134.83 Million
americanbankingnews.com - June 4 at 4:48 AM
Supernus Pharmaceuticals (NASDAQ:SUPN) Could Easily Take On More DebtSupernus Pharmaceuticals (NASDAQ:SUPN) Could Easily Take On More Debt
finance.yahoo.com - June 1 at 12:36 PM
Supernus Pharmaceuticals (NASDAQ:SUPN) Updates FY 2021 Earnings GuidanceSupernus Pharmaceuticals (NASDAQ:SUPN) Updates FY 2021 Earnings Guidance
americanbankingnews.com - May 26 at 2:12 PM
Supernus to Present at Jefferies Virtual Healthcare ConferenceSupernus to Present at Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 25 at 10:08 AM
Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of AgeQelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age
finance.yahoo.com - May 24 at 1:17 PM
Supernus Pharmaceuticals (NASDAQ:SUPN) Releases FY 2021 Earnings GuidanceSupernus Pharmaceuticals (NASDAQ:SUPN) Releases FY 2021 Earnings Guidance
americanbankingnews.com - May 23 at 12:56 AM
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Miss EstimatesSupernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Miss Estimates
finance.yahoo.com - May 6 at 12:05 AM
Supernus Pharmaceuticals Inc (SUPN) Q1 2021 Earnings Call TranscriptSupernus Pharmaceuticals Inc (SUPN) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 6 at 12:05 AM
Supernus Announces First Quarter 2021 Financial ResultsSupernus Announces First Quarter 2021 Financial Results
finance.yahoo.com - May 5 at 7:05 PM
Supernus Announces Paragraph IV ANDA Filing for XADAGO®Supernus Announces Paragraph IV ANDA Filing for XADAGO®
finance.yahoo.com - May 5 at 1:37 AM
SUPN: Raising target price to $34.00SUPN: Raising target price to $34.00
finance.yahoo.com - April 30 at 12:15 AM
Supernus Pharmaceuticals (SUPN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseSupernus Pharmaceuticals (SUPN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
finance.yahoo.com - April 28 at 5:23 PM
Supernus to Host First Quarter 2021 Financial Results Conference CallSupernus to Host First Quarter 2021 Financial Results Conference Call
finance.yahoo.com - April 27 at 10:57 PM
Supernus Pharmaceuticals Reaches Analyst Target PriceSupernus Pharmaceuticals Reaches Analyst Target Price
nasdaq.com - April 14 at 8:41 PM
Supernus shares soar 13% after FDA approves its new ADHD drug for childrenSupernus shares soar 13% after FDA approves its new ADHD drug for children
finance.yahoo.com - April 6 at 12:22 AM
Supernus (SUPN) Receives FDA Approval for ADHD TreatmentSupernus (SUPN) Receives FDA Approval for ADHD Treatment
finance.yahoo.com - April 5 at 2:21 PM
Why Supernus Pharmaceuticals Stock Is Soaring TodayWhy Supernus Pharmaceuticals Stock Is Soaring Today
finance.yahoo.com - April 5 at 2:21 PM
FDA Approves Supernus’ Qelbree; Shares Rise 10% Pre-MarketFDA Approves Supernus’ Qelbree; Shares Rise 10% Pre-Market
finance.yahoo.com - April 5 at 9:21 AM
Supernus Higher as Pediatric ADHD Drug Is Cleared by FDASupernus Higher as Pediatric ADHD Drug Is Cleared by FDA
finance.yahoo.com - April 5 at 9:21 AM
These 2 Scrappy Biotechs Could Skyrocket in AprilThese 2 Scrappy Biotechs Could Skyrocket in April
finance.yahoo.com - April 4 at 7:47 AM
FDA Approves Supernuss Qelbree For Treatment Of Attention-deficit Hyperactivity DisorderFDA Approves Supernus's Qelbree For Treatment Of Attention-deficit Hyperactivity Disorder
nasdaq.com - April 3 at 12:41 AM
Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHDSupernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD
finance.yahoo.com - April 2 at 7:41 PM
3 Healthcare Stocks That Could Be Millionaire-Makers3 Healthcare Stocks That Could Be Millionaire-Makers
finance.yahoo.com - March 24 at 7:17 AM
3 Undervalued Biotechs Worth Adding to Your Watch List3 Undervalued Biotechs Worth Adding to Your Watch List
finance.yahoo.com - February 27 at 6:50 AM
Supernus to Present at Cowen Healthcare ConferenceSupernus to Present at Cowen Healthcare Conference
finance.yahoo.com - February 26 at 1:23 PM
Supernus Pharmaceuticals Inc (SUPN) Q4 2020 Earnings Call TranscriptSupernus Pharmaceuticals Inc (SUPN) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 26 at 1:23 PM
Supernus Pharmaceuticals: Q4 Earnings InsightsSupernus Pharmaceuticals: Q4 Earnings Insights
finance.yahoo.com - February 25 at 10:21 PM
Supernus Announces Fourth Quarter and Full Year 2020 Financial ResultsSupernus Announces Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - February 25 at 5:20 PM
Top-Rated Stocks: Supernus Pharmaceuticals Sees Composite Rating Climb To 96Top-Rated Stocks: Supernus Pharmaceuticals Sees Composite Rating Climb To 96
finance.yahoo.com - February 25 at 12:20 PM
Supernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference CallSupernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call
finance.yahoo.com - February 23 at 9:34 AM
Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDASupernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA
finance.yahoo.com - February 22 at 8:30 AM
Rockville biopharma takes another stab at FDA approval for ADHD drugRockville biopharma takes another stab at FDA approval for ADHD drug
bizjournals.com - February 9 at 8:57 PM
Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric PatientsSupernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients
finance.yahoo.com - February 8 at 12:38 PM
Heres Why I Think Supernus Pharmaceuticals (NASDAQ:SUPN) Might Deserve Your Attention TodayHere's Why I Think Supernus Pharmaceuticals (NASDAQ:SUPN) Might Deserve Your Attention Today
finance.yahoo.com - February 3 at 2:28 PM
SUPN Jun 2021 22.000 callSUPN Jun 2021 22.000 call
ca.finance.yahoo.com - January 23 at 7:07 PM
SUPN Jun 2021 10.000 putSUPN Jun 2021 10.000 put
ca.finance.yahoo.com - January 23 at 7:07 PM
Supernus Pharmaceuticals (SUPN) Investor Presentation - SlideshowSupernus Pharmaceuticals (SUPN) Investor Presentation - Slideshow
seekingalpha.com - January 20 at 6:15 PM
SUPN Jan 2021 32.000 callSUPN Jan 2021 32.000 call
ca.finance.yahoo.com - January 16 at 4:50 PM
Exact Sciences Scores Relative Strength Rating Upgrade; Hits Key ThresholdExact Sciences Scores Relative Strength Rating Upgrade; Hits Key Threshold
finance.yahoo.com - January 12 at 1:16 PM
Supernus to Present at J.P. Morgan 39th Annual Healthcare ConferenceSupernus to Present at J.P. Morgan 39th Annual Healthcare Conference
finance.yahoo.com - January 6 at 8:41 PM
SUPN Mar 2021 30.000 putSUPN Mar 2021 30.000 put
uk.finance.yahoo.com - January 5 at 1:35 AM
Sizing Up Supernus PharmaceuticalsSizing Up Supernus Pharmaceuticals
seekingalpha.com - December 30 at 2:54 PM
Rockville biopharma’s ADHD drug emerges from the clinic with good newsRockville biopharma’s ADHD drug emerges from the clinic with good news
bizjournals.com - December 23 at 3:00 PM
Stock Alert: Supernus Pharmaceuticals Up 14% On Positive Trial Results Of ADHD DrugStock Alert: Supernus Pharmaceuticals Up 14% On Positive Trial Results Of ADHD Drug
nasdaq.com - December 23 at 3:00 PM
Supernus Up on Report of Progress With ADHD TreatmentSupernus Up on Report of Progress With ADHD Treatment
finance.yahoo.com - December 23 at 3:00 PM
Why Supernus Pharmaceuticals Stock Is Rising TodayWhy Supernus Pharmaceuticals Stock Is Rising Today
finance.yahoo.com - December 23 at 3:00 PM
Stocks making the biggest moves in the premarket: Cloudera, Supernus Pharmaceuticals, FuboTV & moreStocks making the biggest moves in the premarket: Cloudera, Supernus Pharmaceuticals, FuboTV & more
cnbc.com - December 23 at 8:36 AM
Why Supernus Shares Rallied 24% After-Hours On TuesdayWhy Supernus Shares Rallied 24% After-Hours On Tuesday
finance.yahoo.com - December 23 at 8:36 AM
Supernus drug meets main goal of study in adults with ADHDSupernus drug meets main goal of study in adults with ADHD
nasdaq.com - December 22 at 11:02 PM
This page was last updated on 6/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.